PIK3CA and carcinoma: Furthermore, EGFR mutations in PSCCE are rare but do exist, especially gefitinib associated mutations such as L858R, therefore gefitinib-based gene targeted therapy at EGFR but not KRAS and PIK3CA genes, probably should be included in this carcinoma treatment regimens for patients harboring L858R mutation.